A virological perspective on the need for vaccination.

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Chronic carriers of hepatitis B virus (HBV) or hepatitis C virus (HCV) are at risk of superinfection with hepatitis A virus (HAV).
• HAV superinfection in these patients often leads to more severe liver disease compared to HAV infection alone.
• Active replication markers of HBV and HCV typically decrease significantly during HAV superinfection.

Purpose of the Study:

• To investigate the immunological mechanisms underlying the more severe liver disease observed in HBV/HCV patients superinfected with HAV.
• To explore the role of interferon-alpha (IFN-alpha) and T helper 1 (Th1) cytokine responses in HAV superinfection.

Main Methods:

• The study proposes a pathogenetic model based on existing literature and immunological principles.
• It discusses the proposed roles of interferon-alpha (IFN-alpha) and T helper 1 (Th1) cytokines (IL-2, IFN-gamma, TNF-alpha) in modulating the immune response.
• Analysis of the association between cytotoxic T-lymphocyte (CTL) responses, cytokine profiles, and viral clearance/persistence.

Main Results:

• Acute HAV infection may induce IFN-alpha, leading to reduced HBV/HCV replication and enhanced CTL responses against HBV/HCV-infected hepatocytes.
• HAV may also stimulate Th1-type cytokines, which directly promote antiviral CTL responses.
• Clearance of HBV, and potentially HAV and HCV, is linked to specific CTL responses, while viral persistence relates to Th1-Th2 imbalance.

Conclusions:

• The enhanced liver damage in HAV superinfection is likely due to induced IFN-alpha and Th1 responses, boosting CTL activity against HBV/HCV.
• Vaccination against hepatitis A is a crucial preventive measure for individuals with chronic HBV or HCV infection.
• Hepatitis A vaccination can mitigate the risk of exacerbating underlying liver disease in chronic HBV/HCV patients.